natgillin/translations-raw huggingface dataset:
It is recommended that SIRTURO is administered by directly observed therapy (DOT). 
Priporočeno je odmerjanje zdravila SIRTURO v okviru neposredno nadzorovanega zdravljenja (DOT - directly observed therapy).
If in vitro testing results are unavailable, treatment may be initiated with SIRTURO in combination with at least four medicinal products to which the patient's isolate is likely to be susceptible. 
Če rezultatov in vitro testiranja ni, se zdravljenje z zdravilom SIRTURO lahko uvede v kombinaciji z vsaj štirimi zdravili, na katere je bolnikov izolat verjetno občutljiv.
When available, the clinical microbiology laboratory should provide the physician with the results of in vitro susceptibility test results for antimicrobial medicinal products used in resident hospitals as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. 
Če je le mogoče, naj klinični mikrobiološki laboratorij zdravniku priskrbi rezultate in vitro testov občutljivosti za protimikrobna zdravila, ki jih uporabljajo v tej bolnišnici, in sicer v obliki periodičnih poročil z opisom profila občutljivosti patogenov, ki povzročajo bolnišnične okužbe in okužbe, pridobljene v domačem okolju (angl. community-acquired).
SIRTURO should be taken orally with food, as administration with food increases oral bioavailability by about 2-fold (see section 5.2). 
Zdravilo SIRTURO je treba jemati peroralno skupaj s hrano, saj jemanje s hrano poveča njegovo biološko uporabnost za približno dvakrat (glejte poglavje 5.2).
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze, malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
• A personal or family history of congenital QT prolongation; 
• z osebno ali družinsko anamnezo prirojenega podaljšanja intervala QT
Because of the potential for adverse reactions in breastfed infants, a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from SIRTURO therapy taking into account the benefit of breast-feeding for the infant and the benefit of therapy for the mother. 
Zaradi možnih neželenih učinkov na dojenega otroka se je treba odločiti, ali naj mati prekine dojenje ali prekine oziroma sploh ne začne zdravljenja z zdravilom SIRTURO, pri čemer je treba upoštevati koristi dojenja za otroka in prednosti zdravljenja za mater.
• A QTcF interval of > 500 ms (confirmed by repeat electrocardiogram). 
• trajanje intervala QTcF > 500 ms (potrjeno s ponovljenim elektrokardiogramom).
There was no effect of maternal treatment with bedaquiline at any dose level on sexual maturation, behavioural development, mating performance, fertility or reproductive capacity of the F1 generation animals. 
Dajanje katerekoli ravni odmerka bedakilina podganjim samicam ni vplivalo na spolno dozorevanje, vedenjski razvoj, parjenje, plodnost ali sposobnost razmnoževanja pri živalih generacije F1.
In animals, bedaquiline and its active N-monodesmethyl metabolite (M2) are extensively distributed to most tissues, however, brain uptake was low. 
Pri živalih se bedakilin in njegov aktivni N-monodesmetilni presnovek (M2) obsežno porazdelita v večino tkiv razen v možgane, kjer je njun privzem majhen.
A carton containing 4 push-through blister strips (containing 6 tablets per strip). 
Škatla vsebuje 4 pretisne trakove (vsak pretisni trak vsebuje 6 tablet).
What you need to know before you take SIRTURO 
Kaj morate vedeti, preden boste vzeli zdravilo SIRTURO
Dizziness has been reported in some patients taking bedaquiline and should be considered when assessing a patient's ability to drive or operate machinery (see section 4.8). 
Pri nekaterih bolnikih, ki so prejemali bedakilin so poročali o omotici, kar je treba upoštevati pri oceni bolnikove sposobnosti za vožnjo in upravljanja s stroji (glejte poglavje 4.8).
In a population pharmacokinetic analysis of tuberculosis patients treated with SIRTURO 200 mg three times a week, creatinine clearance (range: 40 to 227 ml/min) was not found to influence the pharmacokinetic parameters of bedaquiline. 
Po ugotovitvah analize populacijske farmakokinetike pri bolnikih, ki imajo tuberkulozo in jemljejo zdravilo SIRTURO 200 mg trikrat na teden, očistek kreatinina (v obsegu od 40 do 227 ml/min) ni vplival na farmakokinetične parametre bedakilina.
Study C209 evaluated the safety, tolerability, and efficacy of 24 weeks treatment with open-label SIRTURO as part of an individualized treatment regimen in 233 patients who were sputum smear positive within 6 months prior to screening. 
Odprta študija C209 je ocenjevala varnost, prenašanje in učinkovitost 24-tedenskega zdravljenja z zdravilom SIRTURO v sklopu individualizirane sheme zdravljenja pri 233 bolnikih, ki so imeli v obdobju 6 mesecev pred začetnim obiskom (screening) pozitiven izvid razmaza sputuma.
If you have missed a dose and you are not sure what to do, talk to your doctor or pharmacist. 
Če ste pozabili vzeti odmerek in niste prepričani, kako morate ravnati, se posvetujte z zdravnikom ali farmacevtom.
Urinary excretion of bedaquiline is negligible. 
Izločanje bedakilina z urinom je zanemarljivo.
Other medicines and SIRTURO 
Druga zdravila in zdravilo SIRTURO
The basis of assessment of causality between the adverse drug reactions and SIRTURO was not restricted to these trials, but also on review of the pooled Phase I and Phase IIa safety data. 
Ocena vzročne povezave med neželenim učinkom in zdravilom SIRTURO pa ni bila omejena le na podatke iz navedenih študij, ampak je temeljila tudi na pregledu združenih podatkov o varnosti v študijah faze I in II.
Pharmacotherapeutic group: Antimycobacterials, drugs for treatment of tuberculosis, ATC code: J04AK05 
Farmakoterapevtska skupina: Učinkovine za zdravljenje infekcij z mikobakterijami, Zdravila z delovanjem na bakterijo Mycobacterium tuberculosis, oznaka ATC: J04AK05
• QT interval as corrected by the Fridericia method (QTcF) > 450 ms (confirmed by repeat electrocardiogram); 
• z intervalom QT po metodi s korekcijo Fridericia (QTcF) > 450 ms (potrjeno s ponovljenim elektrokardiogramom)
There are limited data on the use of SIRTURO in pregnant women. 
Podatki o uporabi zdravila SIRTURO pri nosečnicah so omejeni.
Three of 24 male rats treated with high bedaquiline doses failed to produce offspring in the fertility study. 
Trije od 24 podganjih samcev, ki so jim v študiji plodnosti dajali visoke odmerke bedakilina, niso mogli zaploditi potomcev.
The elimination of bedaquiline has not been fully characterised in vivo. 
In vivo izločanje bedakilina ni bilo povsem pojasnjeno.
If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking SIRTURO. 
Če karkoli od navedenega velja za vas (ali če o tem niste prepričani), se pogovorite z zdravnikom, s farmacevtom ali z medicinsko sestro, preden vzamete zdravilo SIRTURO.
In a rat carcinogenicity study, bedaquiline, at the high doses of 20 mg/kg/day in males and 10 mg/kg/day in females, did not induce any treatment-related increases in tumour incidences. 
V študiji karcinogenosti pri podganah, bedakilin pri visokih odmerkih 20 mg/kg/dan pri samcih in 10 mg/kg/dan pri samicah ni zvečal z zdravljenjem povezane pojavnosti tumorjev.
Do not take SIRTURO if: 
Ne jemljite zdravila SIRTURO:
What SIRTURO is and what it is used for What you need to know before you take SIRTURO How to take SIRTURO 
Kaj je zdravilo SIRTURO in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo SIRTURO Kako jemati zdravilo SIRTURO Možni neželeni učinki
This low exposure was not considered to be clinically relevant as no clear relationship between exposure to bedaquiline and response has been observed in clinical trials. 
Navedena manjša izpostavljenost ne velja za klinično pomembno, saj v kliničnih študijah niso opažali jasne povezave med izpostavljenostjo bedakilinu in odzivom pri bolnikih.
SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1). 
Zdravilo SIRTURO je indicirano za uporabo kot del ustrezne kombinirane sheme zdravljenja pljučne tuberkuloze, odporne proti več zdravilom (MDR-TB - multidrug-resistant tuberculosis), pri odraslih bolnikih, kadar se učinkovite sheme zdravljenja zaradi odpornosti ali prenosljivosti ne da drugače sestaviti (glejte poglavja 4.2, 4.4 in 5.1).
All but one patients who died of tuberculosis had not converted or had relapsed. 
Pri vseh bolnikih, z izjemo enega bolnika, ki so umrli zaradi tuberkuloze, ni prišlo do konverzije ali pa je prišlo do ponovitve bolezni.
There were no documented cases of Torsade de Pointes in the safety database (see section 4.4). 
V podatkovni bazi o varnosti zdravila ni bilo dokumentiranih primerov pojava torsade de pointes (glejte poglavje 4.4).
If a dose is missed from week three onwards, patients should take the missed dose of 200 mg as soon as possible and then resume the three times a week regimen. 
Če bolnik izpusti odmerek od tretjega tedna dalje, mora izpuščeni odmerek 200 mg vzeti takoj, ko je to mogoče in nato nadaljevati z jemanjem zdravila trikrat na teden.
Paediatric patients The pharmacokinetics of SIRTURO in paediatric patients have not been evaluated. 
Pediatrični bolniki Farmakokinetike zdravila SIRTURO pri pediatričnih bolnikih niso proučevali.
The N-monodesmethyl metabolite (M2) is not thought to contribute significantly to clinical efficacy given its lower average exposure (23% to 31%) in humans and lower antimycobacterial activity (3- to 6-fold lower) compared to the parent compound. 
N-monodesmetilni presnovek (M2)domnevno ne prispeva bistveno h klinični učinkovitosti, saj je povprečna izpostavljenost M2 pri človeku manjša od izpostavljenosti matični spojini (23% do 31%), njegova protibakterijska aktivnost pa je 3 do 6-krat manjša od aktivnosti izhodne učinkovine.
These subjects were excluded from the subgroup analysis by extent of resistance of M tuberculosis strain. 
Ti preiskovanci so bili izključeni iz analize podskupine po obsegu odpornosti sevov M tuberculosis.
Mycobacterium xenopi, Mycobacterium novocastrense, Mycobacterium shimoidei and non-mycobacterial species are considered inherently resistant to bedaquiline. 
Mycobacterium xenopi, Mycobacterium novocastrense, Mycobacterium shimoidei in bakterije, ki ne spadajo med mikobakterije, so opredeljene kot naravno odporne na bedakilin.
Bedaquiline was associated with effects in target organs which included monocytic phagocytic system (MPS), skeletal muscle, liver, stomach, pancreas and heart muscle. 
Bedakilin je deloval na tarčne organe, med katerimi so monocitno-fagocitni sistem (MPS - Monocytic Phagocytic System), skeletne mišice, jetra, želodec, trebušna slinavka in srčna mišica.
Other medicines may affect SIRTURO. 
Druga zdravila lahko vplivajo na delovanje zdravila SIRTURO.
In the SIRTURO group, all of the five deaths due to tuberculosis occurred in patients whose sputum culture status at last visit was ‘not converted'. 
V skupini, ki je prejemala zdravilo SIRTURO je bilo pet smrti posledica tuberkuloze pri bolnikih, katerih kulture sputuma pri zadnjem obisku niso kazale konverzije (odsotnosti povzročitelja v kužnini).
If you are not sure, talk to your doctor or pharmacist before taking SIRTURO. 
Če o tem niste prepričani, se pogovorite z zdravnikom ali farmacevtom, preden vzamete zdravilo SIRTURO.
SIRTURO should be used in combination with at least three medicinal products to which the patient's isolate has been shown to be susceptible in vitro. 
Zdravilo SIRTURO je treba uporabljati v kombinaciji z najmanj tremi zdravili na katere je bolnikov izolat in vitro dokazano občutljiv.
Inherently resistant organisms Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei Non-mycobacterial species 
Naravno odporni organizmi Mycobacterium xenopi Mycobacterium novocastrense Mycobacterium shimoidei
In the SIRTURO group, no or only minor differences in time to culture conversion and culture conversion rates were observed between patients with pre-XDR-TB and patients with MDRH&R-TB. 
V skupini z zdravilom SIRTURO niso opažali razlik oziroma so opažali le manjše razlike v času do konverzije kulture med bolniki s pre-XDR-TB in bolniki z MDRH&R-TB.
efavirenz, etravirine, lopinavir/ritonavir to treat HIV infection (antiretroviral non-nucleoside reverse transcriptase inhibitors, antiretroviral protease inhibitors) 
efavirenz, etravirin, lopinavir/ritonavir za zdravljenje okužbe z virusom HIV (zaviralci ne-nukleozidne reverzne transkriptaze, zaviralci proteaz)
Published data on patients treated with bedaquiline as part of therapy for drugresistant TB and lopinavir/ritonavir-based ART have shown that bedaquiline exposure (AUC) over 48 hours was increased approximately 2 fold. 
Objavljeni podatki bolnikov, ki so prejemali bedakilin kot del sheme zdravljenja tuberkuloze, odporne proti zdravilom skupaj s protiretrovirusnim zdravljenjem na osnovi lopinavirja/ritonavirja so pokazali, da se je izpostavljenost bedakilinu (AUC) po 48 urah povečala za približno 2-krat.
The following are examples of medicines patients with multi-drug resistant tuberculosis may take and which may potentially interact with SIRTURO: 
Spodaj so primeri zdravil, ki jih lahko jemljejo bolniki s tuberkulozo, odporno proti več zdravilom in imajo lahko medsebojen učinek z zdravilom SIRTURO:
• you have had an abnormal heart reading (ECG) or heart failure; 
• če je vaš zapis delovanja srca (EKG) nenormalen ali imate srčno popuščanje
If syncope occurs, an electrocardiogram should be obtained to detect any QT prolongation. 
Ob pojavu sinkope, je potrebno pridobiti elektrokardiogram, da preverite morebitno podaljšanje intervala QT.
The primary outcome parameter was the time to sputum culture conversion (i.e. the interval between the first SIRTURO intake and the first of two consecutive negative liquid cultures from sputum collected at least 25 days apart) during treatment with SIRTURO or placebo (median time to conversion was 83 days for the SIRTURO group, 125 days for the placebo group (hazard ratio, 95% CI: 2.44 [1.57; 3.80]), p < 0.0001). 
Primarni opazovani parameter je bil čas do konverzije kulture sputuma (kar pomeni interval med prejemom prvega odmerka zdravila SIRTURO in prvim od dveh zaporednih negativnih izvidov tekoče kulture iz vzorcev sputuma, ki sta bila odvzeta z najmanj 25-dnevnim presledkom) v času prejemanja zdravila SIRTURO oziroma placeba (mediani čas do konverzije je bil 83 dni za skupino, ki je prejemala zdravilo SIRTURO, 125 dni za skupino, ki je prejemala placebo (razmerje tveganja, 95% IZ: 2,44 [1,57; 3,80]), p < 0,0001).
As a precautionary measure, avoid the use of SIRTURO during pregnancy unless the benefit of therapy is considered to outweigh the risks. 
Iz previdnostnih razlogov se med nosečnostjo zogibajte uporabi zdravila SIRTURO, razen v primeru, da ocenjene koristi zdravljenja presegajo tveganja.
At both week 24 and week 120, responder rates were higher for patients on 3 or more active substances (in vitro) in their background regimen. 
Stopnja odziva po 24. in 120. tednu je bila večja pri bolnikih, ki so v okviru osnovne sheme zdravljenja prejemali 3 ali več zdravilnih učinkovin (in vitro).
Patients received SIRTURO (n = 79) or placebo (n = 81) for 24 weeks, both in combination with a preferred 5-drug background regimen (BR) consisting of ethionamide, kanamycin, pyrazinamide, ofloxacin, and cycloserine/terizidone. 
Bolniki so 24 tednov prejemali zdravilo SIRTURO (n = 79) ali placebo (n = 81) v kombinaciji z osnovno shemo (BR), ki jo je sestavljalo 5 preferenčnih učinkovin: etionamid, kanamicin, pirazinamid, ofloksacin in cikloserin/terizidon.
In rats, concentrations of bedaquiline in milk were 6- to 12-fold higher than the maximum concentration observed in maternal plasma. 
Pri podganah je bila koncentracija bedakilina v mleku 6 do 12-krat višja od najvišje koncentracije, ki so jo izmerili v plazmi mater.
A Phase IIb, placebo-controlled, double-blind, randomised trial (C208) evaluated the antibacterial activity, safety, and tolerability of SIRTURO in newly diagnosed patients with sputum smear-positive pulmonary MDRH&R- and pre-XDR-TB. 
V s placebom nadzorovanem, dvojno slepem, randomiziranem preskušanju faze IIb (študija C208) so ocenjevali protibakterijsko aktivnost, varnost in prenašanje zdravila SIRTURO pri novo odkritih bolnikih s pozitivnim izvidom razmaza sputuma na prisotnost pljučne MDRH&R-TB in pre-XDR-TB.
• The other ingredients are: colloidal anhydrous silica, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polysorbate 20. 
• Druge sestavine zdravila so: brezvoden koloidni silicijev dioksid, premrežen natrijev karmelozat, hipromeloza, laktoza monohidrat, magnezijev stearat, koruzni škrob, mikrokristalna celuloza, polisorbat 20.
The European Medicines Agency has deferred the obligation to submit the results of studies with SIRTURO in one or more subsets of the paediatric population in the treatment of multi-drug resistant Mycobacterium tuberculosis (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom SIRTURO za eno ali več podskupin pediatrične populacije za zdravljenje okužbe z bakterijo Mycobacterium tuberculosis, odporno na več zdravil (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In a study in 44 healthy subjects receiving a single 800 mg dose of SIRTURO, adverse reactions were consistent with those observed in clinical studies at the recommended dose (see section 4.8). 
V študiji s 44 zdravimi osebami, ki so prejele enkraten odmerek 800 mg zdravila SIRTURO, so bili neželeni učinki podobni tistim, ki so jih opažali v kliničnih študijah pri uporabi priporočenih odmerkov (glejte poglavje 4.8).
Other hepatotoxic medicinal products and alcohol should be avoided while on SIRTURO, especially in patients with diminished hepatic reserve. 
V času zdravljenja z zdravilom SIRTURO se je treba izogibati uporabi drugih zdravil s toksičnim delovanjem na jetra in alkoholu, kar zlasti velja za bolnike z zmanjšano rezervo delovanja jeter.
Do not give this medicine to children and adolescents (under 18 years of age). 
Tega zdravila ne smete dajati otrokom ali mladostnikom (starim manj kot 18 let), ker zdravila v tej starostni skupini bolnikov niso proučevali.
The other nine deaths among those treated with SIRTURO occurred after completion of treatment with this agent (range 86 911 days post SIRTURO; median 344 days). 
Do ostalih devetih smrti v tej skupini je prišlo po zaključku zdravljenja (razpon 86-911 dni; mediana 344 dni po zaključku zdravljenja z zdravilom SIRTURO).
Bedaquiline specifically inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, an essential enzyme for the generation of energy in Mycobacterium tuberculosis. 
Bedakilin specifično zavira mikobakterijsko ATP-sintazo (adenozin-5'-trifosfat sintazo), encim, ki ga bakterija Mycobacterium tuberculosis nujno potrebuje za pridobivanje energije.
The imbalance in deaths is unexplained; no evidence has been found for a causal relationship with SIRTURO treatment. 
Nesorazmerje v številu smrti ni pojasnjeno in vzročne povezave z zdravljenjem z zdravilom SIRTURO niso ugotovili.
Co-administration of bedaquiline and medicinal products that induce CYP3A4 may decrease bedaquiline plasma concentrations and reduce its therapeutic effect. 
Sočasna uporaba bedakilina in zdravil, ki inducirajo encim CYP3A4, lahko zniža koncentracijo bedakilina v plazmi in zmanjša njegov terapevtski učinek.
SIRTURO was administered as 400 mg once daily for the first 2 weeks, and as 200 mg 3 times/week for the following 22 weeks. 
Bolniki so prva 2 tedna prejemali 400 mg zdravila SIRTURO enkrat na dan, nadaljnjih 22 tednov pa 200 mg 3-krat na teden.
• latent infection with Mycobacterium tuberculosis 
• latentne okužbe z bakterijo Mycobacterium tuberculosis.
Compared to the exposures (AUC) observed in subjects with MDR-TB in the bedaquiline phase II trials, the exposures (AUC) in rats at high doses were similar in males and 2-fold higher in females for bedaquiline, and 3-fold higher in males and 2-fold higher in females for M2. 
V primerjavi z izpostavljenostjo zdravilu (AUC), opaženo pri preiskovancih z MDR-TB v študijah faze II z bedakilinom, je bila izpostavljenost (AUC) bedakilinu pri podganah ob uporabi visokih odmerkov podobna pri samcih in 2-krat večja pri samicah, izpostavljenost M2 pa 3-krat večja pri samcih in 2-krat večja pri samicah.
After the 24-week investigational period, the background regimen was continued to complete 18 to 24 months of total multi-drug resistant Mycobacterium tuberculosis treatment. 
Po zaključku 24-tedenskega raziskovalnega obdobja so bolniki nadaljevali zdravljenje z osnovno shemo zdravil in tako zaključili zdravljenje okužbe s proti več zdravilom odporno bakterijo Mycobacterium tuberculosis, ki je trajalo skupno 18 do 24 mesecev.
If you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine. 
Če ne prenašate ali ne morete prebavljati nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
These lead to 2- to 8-fold increases in bedaquiline MICs, resulting in bedaquiline MICs ranging from 0.25 to 0.5 mg/l. 
Te vodijo v 2 do 8-kratno zvečanje MIK bedakilina, s koncentracijami od 0,25 do 0,5 mg/l.
In the MPS of all species, pigment-laden and/or foamy macrophages were also seen in various tissues, consistent with phospholipidosis. 
V monocitno-fagocitnem sistemu so pri vseh živalskih vrstah v različnih tkivih opažali s pigmentom napolnjene in/ali penaste makrofage, kar ustreza fosfolipidozi.
Follow-up monitoring of electrolytes should be performed if QT prolongation is detected (see sections 4.5 and 4.8). 
Če pride do podaljšanja intervala QT je potrebno ponovno preveriti koncentracije elektrolitov (glejte poglavji 4.5 in 4.8).
No human data on the effect of bedaquiline on fertility are available. 
Podatki o vplivu bedakilina na plodnost pri ljudeh niso na voljo.
The MAH will evaluate additional efficacy and safety data of bedaquiline in different treatment regimen compared to a regimen that does not include bedaquiline (confirmatory phase III study) following an agreed protocol. 
Skladno z dogovorjenim protokolom bo MAH izvedel oceno dodatnih podatkov o učinkovitosti in varnosti bedakilina pri različnih režimih zdravljenja, v primerjavi z režimi, ki ne vsebujejo bedakilina (potrditvena študija faze III).
There are no data to support a lowered bedaquiline dose in such circumstances. 
V teh primerih ni podatkov, ki bi podpirali zmanjšanje odmerka bedakilina.
Efavirenz is a moderate inducer of CYP3A4 activity and co-administration with bedaquiline may result in reduced bedaquiline exposure and loss of activity, and is, therefore, not recommended. 
Efavirenz je zmeren induktor aktivnosti CYP3A4 in pri sočasni uporabi z bedakilinom lahko pride do zmanjšane izpostavljenosti bedakilinu ter izgube njegove učinkovitosti, zato sočasna uporaba ni priporočena.
The pharmacokinetic properties of bedaquiline have been evaluated in adult healthy subjects and in adult multi-drug resistant tuberculosis-infected patients. 
Farmakokinetične lastnosti bedakilina so ocenjevali pri odraslih zdravih osebah in pri odraslih bolnikih s tuberkulozo, odporno na več zdravil.
Removal of unabsorbed bedaquiline may be aided by the administration of activated charcoal. 
Neabsorbiran bedakilin je mogoče odstranjevati z uporabo aktivnega oglja.
After treatment cessation, all indications of toxicity exhibited at least partial recovery to good recovery. 
Po prekinitvi zdravljenja je pri vseh znakih toksičnega delovanja prišlo do vsaj delnega izboljšanja, pri nekaterih pa je bilo izboljšanje precejšnje.
From week 3 onwards 
Od 3. tedna dalje